Financials (USD)
Sales 2024 * | 681M | Sales 2025 * | 837M | Capitalization | 2.87B |
---|---|---|---|---|---|
Net income 2024 * | -109M | Net income 2025 * | -6M | EV / Sales 2024 * | 3.9 x |
Net cash position 2024 * | 217M | Net cash position 2025 * | 346M | EV / Sales 2025 * | 3.01 x |
P/E ratio 2024 * |
-24.8
x | P/E ratio 2025 * |
522
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on HUTCHISON CHINA MED.
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 04-12-31 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 08-06-30 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 99-12-31 |
Graeme Jack
BRD | Director/Board Member | 73 | 17-02-28 |
Dan Eldar
BRD | Director/Board Member | 70 | 16-07-31 |
1st Jan change | Capi. | |
---|---|---|
+28.79% | 676B | |
+24.47% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+3.19% | 210B | |
-0.25% | 204B | |
-9.49% | 194B | |
-11.71% | 144B |